Abstract
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
Original language | English |
---|---|
Pages (from-to) | 283-292 |
Number of pages | 10 |
Journal | Anti-Cancer Agents in Medicinal Chemistry |
Volume | 10 |
Issue number | 4 |
Publication status | Published - May 2010 |
Keywords
- Anticancer drug
- Dithiocarbamate
- Gold compounds
- Metallodrug
- Nephrotoxicity
- Proteasome inhibitor
- Reactive oxygen species (ROS)
- Thioredoxin reductase (TrxR)
ASJC Scopus subject areas
- Cancer Research
- Molecular Medicine
- Pharmacology